Compare LAW & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | ASMB |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.2M | 414.7M |
| IPO Year | 2021 | 2010 |
| Metric | LAW | ASMB |
|---|---|---|
| Price | $3.77 | $27.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $9.00 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 286.9K | 98.0K |
| Earning Date | 02-25-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $152,677,000.00 | $37,191,000.00 |
| Revenue This Year | $8.54 | $33.33 |
| Revenue Next Year | $9.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.33 | ★ 31.30 |
| 52 Week Low | $3.31 | $7.75 |
| 52 Week High | $9.11 | $39.71 |
| Indicator | LAW | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 14.85 | 44.89 |
| Support Level | $3.61 | $25.14 |
| Resistance Level | $6.52 | $27.48 |
| Average True Range (ATR) | 0.41 | 1.71 |
| MACD | -0.26 | 0.20 |
| Stochastic Oscillator | 5.02 | 46.51 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.